Shingrix in 2017 received US FDA approval to prevent shingles in adults aged 50 and older. Since 2021, it has been approved for use in immunocompromised patients aged 18 and up. GSK estimates around ...
GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...
GlaxoSmithKline (GSK) is to collaborate with the Francis Crick Institute, a new powerhouse of academic- and charity-funded biomedical research based in London. The new partnership is expected to ...
Bloomberg on MSN7mon
GSK’s New Vaccine Kept the Boss in Her Job — and an Activist at BayWalmsley’s efforts ruffled feathers, and morale was initially low at GSK’s research hub in Stevenage, north of London. In an ...
(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration has granted a breakthrough therapy designation to its treatment for a form of bone cancer.
London: GSK plc has announced that the US Food and Drug Administration (USFDA) has granted Breakthrough Therapy Designation ...
GSK has announced that the FDA has accepted its application to review a prefilled syringe version of Shingrix, its shingles vaccine. This new ver ...
LONDON - GSK plc (LSE/NYSE: LON:GSK) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational drug GSK'227, aimed at treating adults with ...
Lacalle Pou “welcomed GSK's announcement of the opening of one ... The UK “encouraged exploring the cross-issuance of this bond in London to access the ample global capital funds present ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback